JP2022501315A5 - - Google Patents

Info

Publication number
JP2022501315A5
JP2022501315A5 JP2021506258A JP2021506258A JP2022501315A5 JP 2022501315 A5 JP2022501315 A5 JP 2022501315A5 JP 2021506258 A JP2021506258 A JP 2021506258A JP 2021506258 A JP2021506258 A JP 2021506258A JP 2022501315 A5 JP2022501315 A5 JP 2022501315A5
Authority
JP
Japan
Prior art keywords
benzamide
diethylamino
ethyl
compound
formula
Prior art date
Application number
JP2021506258A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020035554A5 (https=
JP2022501315A (ja
JP7512251B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/071903 external-priority patent/WO2020035554A1/en
Publication of JP2022501315A publication Critical patent/JP2022501315A/ja
Publication of JPWO2020035554A5 publication Critical patent/JPWO2020035554A5/ja
Publication of JP2022501315A5 publication Critical patent/JP2022501315A5/ja
Application granted granted Critical
Publication of JP7512251B2 publication Critical patent/JP7512251B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506258A 2018-08-15 2019-08-15 病的炎症の新しい医療 Active JP7512251B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18189194 2018-08-15
EP18189194.6 2018-08-15
PCT/EP2019/071903 WO2020035554A1 (en) 2018-08-15 2019-08-15 A new medical treatment for pathologic inflammation

Publications (4)

Publication Number Publication Date
JP2022501315A JP2022501315A (ja) 2022-01-06
JPWO2020035554A5 JPWO2020035554A5 (https=) 2022-08-17
JP2022501315A5 true JP2022501315A5 (https=) 2022-08-17
JP7512251B2 JP7512251B2 (ja) 2024-07-08

Family

ID=63294023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506258A Active JP7512251B2 (ja) 2018-08-15 2019-08-15 病的炎症の新しい医療

Country Status (10)

Country Link
US (1) US11896564B2 (https=)
EP (1) EP3836912B1 (https=)
JP (1) JP7512251B2 (https=)
CN (1) CN112770736B (https=)
AU (1) AU2019322564A1 (https=)
BR (1) BR112021001984A2 (https=)
CA (1) CA3108361A1 (https=)
IL (1) IL280548A (https=)
MX (1) MX2021001349A (https=)
WO (1) WO2020035554A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703036B (zh) * 2018-08-15 2025-05-27 法玛西尔有限公司 取代的苯甲酰胺及其在疗法中的用途
US11717500B2 (en) * 2020-02-03 2023-08-08 Pharmacyl Ab Treatment of spondyloarthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281394A (https=) 1961-07-25
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6100299A (en) 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US6518312B2 (en) 2000-07-05 2003-02-11 Active Biotech Ab Immune enhancement
US7157444B2 (en) 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
WO2005025498A2 (en) 2003-09-08 2005-03-24 Corus Pharma Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
DE102004011720B4 (de) 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
CA2649256C (en) * 2006-04-13 2013-09-10 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease
RU2469724C2 (ru) * 2007-12-18 2012-12-20 Мейдзи Сейка Фарма Ко., Лтд. Профилактическое или терапевтическое вещество при воспалительных болезнях кишечника
WO2018037103A1 (en) * 2016-08-26 2018-03-01 Idogen Ab Procainamide for treating immune disorders and for modulating ido expression

Similar Documents

Publication Publication Date Title
HRP20120505T1 (hr) Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
HRP20241768T1 (hr) Heterociklički spoj
JP2017537940A5 (https=)
HRP20210726T1 (hr) Ciklički dinukleotidi kao antagonisti sting (stimulatora interferonskih gena)
HRP20240157T1 (hr) Deuterirani derivati lanifibranora
JP2017523225A5 (https=)
JP2018533593A5 (https=)
JP2015024998A5 (https=)
JP2014502979A5 (https=)
JP2010524947A5 (https=)
HRP20090577T8 (en) Use of crth2 antagonist compounds in therapy
SI2743266T1 (en) Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis
JP2020502047A5 (https=)
JP2014062126A5 (https=)
JP2015535847A5 (https=)
RU2015121424A (ru) Комбинированная терапия
JP2017504595A5 (https=)
JP2019531279A5 (https=)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
HRP20241558T1 (hr) Dvojni inhibitori magl i faah
JP2015508068A5 (https=)
JP2022501315A5 (https=)
RU2010115337A (ru) Трициклические гетероциклические производные
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы